Submission declined on 17 July 2026 by ChrysGalley (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content. LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that: provide significant coverage: discuss the subject in detail, excluding routine coverage like product launches, staff appointments, or financial reports and listings in databases or listicles; are reliable: from reputable outlets with editorial oversight; are independent: not connected to the subject, such as press releases, the subject's own website, or sponsored content. Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia. If you would like to continue working on the submission, click on the "Edit" tab at the top of the window. If you have not resolved the issues listed above, your draft will be declined again and potentially deleted. If you need extra help, please ask us a question at the AfC Help Desk or get live help from experienced editors. Please do not remove reviewer comments or this notice until the submission is accepted. Where to get help If you need help editing or submitting your draft, please ask us a question at the AfC Help Desk or get live help from experienced editors. These venues are only for help with editing and the submission process, not to get reviews. If you need feedback on your draft, or if the review is taking a lot of time, you can try asking for help on the talk page of a relevant WikiProject. Some WikiProjects are more active than others so a speedy reply is not guaranteed. How to improve a draft Wikipedia:Contributing to Wikipedia – a basic overview on how to edit Wikipedia. Help:Wikitext – how to use the markup Help:Referencing for beginners – how to include references Wikipedia:Article development – how to develop your article Wikipedia:Writing better articles – how to improve your article Wikipedia:Verifiability – make sure your article includes reliable third-party sources You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Add tags to your draft Editor resources Easy tools: Citation bot (help) | Advanced: Fix bare URLs Declined by ChrysGalley 31 days ago. Last edited by ChrysGalley 31 days ago. Reviewer: Inform author. Resubmit Please note that if the issues are not fixed, the draft will be declined again.

Submission declined on 17 July 2026 by EaglesFan37 (talk). This draft appears to contain text generated by a large language model (such as ChatGPT). You cannot use LLMs to generate article content. LLM-generated pages with certain obvious signs of being machine generated may be deleted without notice. Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. See the advice page on large language models for more information. Declined by EaglesFan37 31 days ago.

• Comment: Still AI generated text here.
  In addition this draft is not showing corporate depth per WP:NCORP. ChrysGalley (talk) 20:45, 17 July 2026 (UTC)

'

Syndicate Bio is a biotechnology company headquartered in Newark, Delaware, with operations centered in Lagos, Nigeria. Founded in 2023, the company focuses on genomic data collection, diagnostics, and precision medicine research within African populations.^[1][2]

Syndicate Bio was founded in March 2023 and announced its launch in September 2023. The company was founded by Abasi Ene-Obong, a Nigerian biomedical scientist who previously founded 54gene, an African genomics startup that ceased operations in 2023. The company was co-founded alongside Jumi Popoola, who serves as scientific advisor, and Estelle Dogbo, who serves as chief operating officer.^[2] The company was established shortly after the liquidation of 54gene, with its founders stating a goal to continue genomic research on the African continent under a modified operational model.^[3]

Since its launch, Syndicate Bio has entered into several agreements with government agencies, research institutes, and private corporations. In October 2023, the company signed a Memorandum of Understanding (MoU) with the Nigerian Institute of Medical Research (NIMR) to study infectious and non-infectious diseases.^[4] Syndicate Bio, in November 2023 partnered with the National Institute for Cancer Research and Treatment (NICRAT) in Nigeria to launch a program termed Cancer Genome Nigeria, which aims to study cancer genetics within the country.^[2] In April 2024 The company partnered with Swiss-American health technology firm Sophia Genetics to implement liquid biopsy testing and genomic profiling in its laboratory facilities.^[5]

The company's research focus is based on the existing disparity in global genomic databases. According to research published in major scientific journals, African descents make up less than 3% of the genomic data utilized in global genome-wide association studies (GWAS).^[1] Syndicate Bio aims to address this gap by collecting and analyzing genomic, proteomic, and metabolomic data from African cohorts to study disease risks and drug efficacy.^[2][5]

The company operates through two primary frameworks:

Direct by Syndicate Bio: A digital portal used by healthcare providers to order genetic tests, including non-invasive prenatal screening (NIPS) and cancer risk profiling, which equips patients and doctors with actionable genetic insights to enable personalized cancer care, early disease detection, and tailored treatments.^[3][6]

Precision54 Clinical Hub: A research network that coordinates clinical trials and observational studies in partnership with local healthcare institutions. It facilitates cutting-edge clinical trials, streamlines study startup times, and allows African medical professionals to actively participate in global drug discovery and development.^[1]

According to its corporate policies, Syndicate Bio operates under specific data sharing and sample management guidelines. Participants in research studies must provide informed consent, with the stated right to withdraw their data from the company's database.^[1] The company also states that raw physical biological samples collected during research are retained within local African jurisdictions rather than being exported or sold externally.^[1][5]